Arcellx (ACLX) Competitors

Arcellx (NASDAQ:ACLX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.

Does the MarketBeat Community believe in ACLX or GMAB?

Genmab A/S received 96 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 62.84% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Arcellx	Outperform Votes 68 82.93%	Underperform Votes 14 17.07%
Genmab A/S	Outperform Votes 164 62.84%	Underperform Votes 97 37.16%

Does the media prefer ACLX or GMAB?

In the previous week, Genmab A/S had 14 more articles in the media than Arcellx. MarketBeat recorded 18 mentions for Genmab A/S and 4 mentions for Arcellx. Genmab A/S's average media sentiment score of 1.00 beat Arcellx's score of 0.96 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcellx	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ACLX or GMAB?

Arcellx has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Do analysts rate ACLX or GMAB?

Arcellx presently has a consensus price target of $105.93, indicating a potential upside of 66.16%. Genmab A/S has a consensus price target of $42.17, indicating a potential upside of 88.75%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.13
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Is ACLX or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Arcellx's net margin of -25.94%. Genmab A/S's return on equity of 16.78% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-25.94%	-8.28%	-5.21%
Genmab A/S	36.30%	16.78%	13.79%

Do insiders and institutionals hold more shares of ACLX or GMAB?

96.0% of Arcellx shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 6.2% of Arcellx shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better valuation & earnings, ACLX or GMAB?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$110.32M	31.25	-$70.69M	-$0.71	-89.79
Genmab A/S	$21.53B	0.69	$1.14B	$1.74	12.84

Summary

Genmab A/S beats Arcellx on 12 of the 19 factors compared between the two stocks.